Prosensa Technologies B.V.
Records under this name other than patents Prosensa Technologies B.V. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Prosensa Technologies B.V.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,890,379 | Treatment of Genetic Disorders Associated with DNA Repeat Instability Formerly held In force · High confidence | In force | High confidence | |
| US 10,689,646 | Treatment Of Genetic Disorders Associated With DNA Repeat Instability Formerly held In force · High confidence | In force | High confidence | |
| US 11,274,299 | Methods and means for treating DNA repeat instability associated genetic disorders Formerly held In force · High confidence | In force | High confidence | |
| US 8,519,097 | Molecules for targeting compounds to various selected organs or tissues Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,499,818 | Methods and Means for Efficient Skipping of at Least One of the Exons 51-53, 55, 57 and 59 of the Human Duchenne Muscular Dystrophy Gene Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 9,926,557 | METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA Formerly held In force · Medium confidence | In force | Medium confidence | |
| US RE48,468 | Means and methods for counteracting muscle disorders Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,139,828 | Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,246,707 | Method for Efficient Exon (44) Skipping in Duchenne Muscular Dystrophy and Associated Means Formerly held In force · Low confidence | In force | Low confidence | |
| US 10,533,171 | Oligonucleotide comprising an inosine for treating DMD Formerly held In force · From the USPTO record | In force | From the USPTO record |